A biopharmaceutical company focused on creating differentiated, value-added vaccines that improve upon current preventive options for a range of infectious diseases.


Updates from The Motley Fool

Latest updates on Novavax from Fool.com.  The Fool has written over 200 articles on Novavax.
3 Great Stocks Under $10

It's not the low share price that makes these stocks attractive, it's their huge growth prospects.

Why Novavax Is Up 60% in 2018

Good news for its top experimental vaccines put the wind in the sails for this clinical-stage bio...

Why Novavax Soared Today

The clinical-stage biotech stock appeared to get a bump from three separate reports.

Why Novavax Stock Buckled in June

Novavax's stock got blasted by geopolitical headwinds last month, but that doesn't mean it's now ...

3 Top Stocks Under $5

These low-priced stocks could generate huge returns. But there are huge risks, too.



Stock Performance

View Interactive NVAX Charts
Sponsored by

Key Data Points

Primary metrics and data points about Novavax.
Current Price: $2.12
Prev Close: $2.08
Open: $2.12
Bid: $2.12
Ask: $2.14
Day's Range: $2.08 - $2.15
52wk Range: $1.15 - $2.75
Volume: 9,462,103
Avg Vol 10,840,474
Market Cap: $665M
P/E (ttm): -3.92
EPS (ttm): -$0.53
Div & Yield: $0.00 (0.0%)

Company Rating

What our community thinks about Novavax.
CAPS Rating 2 out of 5
 
309 Outperform
84 Underperform
CAPS All Stars
 
35 Outperform
19 Underperform

How do you think Novavax will perform against the market?



You pick for Novavax is winning

Score: +97.74
Call: Outperform
Time Frame: Five Plus Years
Start Price: $18.24
Start Date: 3/29/2007
Gain/Loss: +$152.4%
S&P Gain/Loss: +$54.7%

Powered by Motley Fool CAPS


CEO Rating

The single most important factor in a company's success is the team that's leading the company.

Stanley C. Erck, CEO

83% Approve

Based on 37 Ratings

Powered by Glassdoor

Business Summary

Industry, sector and description for Novavax.

A biopharmaceutical company focused on creating differentiated, value-added vaccines that improve upon current preventive options for a range of infectious diseases.

  • Exchange: NASDAQ
  • Sector: Healthcare
  • Industry: Drug Makers